| Patents for A61P 27 - Drugs for disorders of the senses (53,017) |
|---|
| 06/07/2001 | WO2001040472A2 Streptococcus pneumoniae antigens |
| 06/07/2001 | WO2001040457A1 Semaphorin receptor |
| 06/07/2001 | WO2001040251A1 Transforming growth factor alpha hiii |
| 06/07/2001 | WO2001040231A1 Heterocyclic dihydropyrimidines as potassium channel inhibitors |
| 06/07/2001 | WO2001040217A1 Novel benzoimidazole derivatives useful as antiproliferative agents |
| 06/07/2001 | WO2001040216A1 Heterocyclo-alkylsulfonyl pyrazole derivatives as anti-inflammatory/analgesic agents |
| 06/07/2001 | WO2001040185A1 Compounds, compositions, and methods for stimulating neuronal growth and elongation |
| 06/07/2001 | WO2001039805A1 Concomitant drugs for treating glaucoma |
| 06/07/2001 | WO2001039792A2 The use of caspase 9 inhibitors to treat ocular neural pathology |
| 06/07/2001 | WO2001039777A1 Compounds specific to adenosine a1 a2a, and a3 receptors and uses thereof |
| 06/07/2001 | WO2001028557B1 Cannabimimetic indole derivatives |
| 06/07/2001 | WO2001008667A3 2-aminotetralin derivatives for the therapy of glaucoma |
| 06/07/2001 | WO2000074703B1 Therapeutic agent comprising a botulinum neurotoxin |
| 06/07/2001 | DE19952146A1 Arylalkane, Arylalkene und Aryl-azaalkane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung Arylalkanes, aryl alkenes and aryl azaalkane, pharmaceutical compositions containing them and methods for their preparation |
| 06/07/2001 | CA2393179A1 Compounds specific to adenosine a1 a2a, and a3 receptors and uses thereof |
| 06/07/2001 | CA2392991A1 Semaphorin receptor |
| 06/07/2001 | CA2392963A1 Methods for identifying compounds for motion sickness, vertigo and other disorders related to balance and the perception of gravity |
| 06/07/2001 | CA2392931A1 Heterocyclo-alkylsulfonyl pyrazole derivatives as anti-inflammatory/analgesic agents |
| 06/07/2001 | CA2392895A1 Streptococcus pneumoniae antigens |
| 06/07/2001 | CA2390839A1 Transforming growth factor alpha hiii |
| 06/07/2001 | CA2389368A1 Compounds, compositions, and methods for stimulating neuronal growth and elongation |
| 06/07/2001 | CA2327638A1 Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications |
| 06/07/2001 | CA2327575A1 Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications |
| 06/06/2001 | EP1104760A1 Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents |
| 06/06/2001 | EP1104759A1 Heteroaryl phenyl pyrazole compounds as anti-inflammatory/analgesic agents |
| 06/06/2001 | EP1104758A1 Acetylene derivatives as anti-inflammatory/analgesic agents |
| 06/06/2001 | EP1104464A2 Nucleic acids encoding a functional human purinoreceptor p2x2 and methods of producing and use thereof |
| 06/06/2001 | EP1104412A1 Tace inhibitors |
| 06/06/2001 | EP1104407A1 Compounds as selective agonists at alpha 2b or 2b/2c adrenergic receptors |
| 06/06/2001 | EP1104403A1 Hydroxy pipecolate hydroxamic acid derivatives as mmp inhibitors |
| 06/06/2001 | EP1104402A1 Pipecolic acid derivatives and their use for vision and memory disorders |
| 06/06/2001 | EP1104302A1 Prophylactic treatments of neovascularisation in macular degeneration |
| 06/06/2001 | EP1104299A2 N-linked urea or carbamate of heterocyclic thioesters for vision and memory disorders |
| 06/06/2001 | EP1104298A2 Heterocyclic thioesters or ketones for vision and memory disorders |
| 06/06/2001 | CN1298411A Caspase-8 interacting proteins |
| 06/06/2001 | CN1298304A Pharmaceutical composition for prophylaxis and therapy of diseases associated with ocular fundus tissue cytopathy |
| 06/06/2001 | CN1298302A Topical administration of oxazolidinones for transdermal delivery |
| 06/06/2001 | CN1298295A Method and compositions for stabilizing acetylcholine compositions |
| 06/05/2001 | US6242637 Substituted heterocylic compounds, method of preparing them and pharmaceutical compositions in which they are present |
| 06/05/2001 | US6242601 Heterocyclic sulfamides |
| 06/05/2001 | US6242480 Ophthalmic viscoelastic compositions |
| 06/05/2001 | US6242479 Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of disease |
| 06/05/2001 | US6242441 Use of brinzolamide to prevent visual field loss |
| 06/05/2001 | US6242198 Methods of treatment of eye trauma and disorders |
| 06/03/2001 | CA2327385A1 Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents |
| 06/03/2001 | CA2327256A1 Heteroaryl phenyl pyrazole compounds as anti-inflammatory/analgesic agents |
| 05/31/2001 | WO2001038878A2 Pin1 as a marker for abnormal cell growth |
| 05/31/2001 | WO2001038566A2 Screening method for candidate drugs |
| 05/31/2001 | WO2001038503A2 Novel human protein kinases and protein kinase-like enzymes |
| 05/31/2001 | WO2001038397A1 N-alkylated peptides having antiangiogenic activity |
| 05/31/2001 | WO2001038347A2 Peptides having antiangiogenic activity |
| 05/31/2001 | WO2001038326A2 Imidazo-pyridine derivatives as ligands for gaba receptors |
| 05/31/2001 | WO2001038325A1 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity |
| 05/31/2001 | WO2001038324A2 Imidazole derivatives and their use as raf kinase inhibitors |
| 05/31/2001 | WO2001038320A1 Vitamin d analogues |
| 05/31/2001 | WO2001038314A1 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors |
| 05/31/2001 | WO2001038313A1 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/p39 kINASE INHIBITORS |
| 05/31/2001 | WO2001038312A1 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/p38 KINASE INHIBITORS |
| 05/31/2001 | WO2001038311A2 Pyrimidine derivatives as selective inhibitors of cox-2 |
| 05/31/2001 | WO2001038303A2 Vitamin d analogues |
| 05/31/2001 | WO2001037846A1 Method and composition for the treatment of adenoviral ocular infections |
| 05/31/2001 | WO2001037838A1 Ophthalmic aqueous preparation |
| 05/31/2001 | WO2001037837A1 3,4-DIHYDRO-(1H)-QUINAZOLIN-2-ONES AND THEIR USE AS CSBP/p38 KINASE INHIBITORS |
| 05/31/2001 | WO2001037835A1 Novel compounds |
| 05/31/2001 | WO2001037830A1 Method for increasing the concentration of ascorbic acid in brain tissues of a subject |
| 05/31/2001 | WO2001037806A1 Composition and method for treatment of otitis media |
| 05/31/2001 | WO2000073307A3 Substituted 8-phenylxanthines useful as antagonists of a2b adenosine receptors |
| 05/31/2001 | WO2000071140A3 Methods and compositions for modulating immune response and for the treatment of inflammatory disease |
| 05/31/2001 | WO2000063222A3 Novel ribose-substituted aromatic amides, method for the production and use thereof as medicaments |
| 05/31/2001 | WO2000061754A3 Human proteins and polynucleotides encoding them |
| 05/31/2001 | WO2000010507A3 Use of melanin for inhibition of angiogenesis and macular degeneration |
| 05/31/2001 | WO2000009512A3 Bipyridine manganese complexes |
| 05/31/2001 | WO1999064041A9 Multibinding agents that modulate nmda receptors |
| 05/31/2001 | US20010002400 Administering an antifungal agent |
| 05/31/2001 | CA2395564A1 Novel compounds |
| 05/31/2001 | CA2395049A1 Pyrimidine derivatives as selective inhibitors of cox-2 |
| 05/31/2001 | CA2394803A1 Novel human protein kinases and protein kinase-like enzymes |
| 05/31/2001 | CA2392365A1 Method for increasing the concentration of ascorbic acid in brain tissues of a subject |
| 05/31/2001 | CA2392327A1 Imidazo-pyridine derivatives as ligands for gaba receptors |
| 05/31/2001 | CA2391386A1 Peptides having antiangiogenic activity |
| 05/31/2001 | CA2390923A1 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity |
| 05/31/2001 | CA2386893A1 N-alkylated peptides having antiangiogenic activity |
| 05/30/2001 | EP1102842A2 Antisense oligonucleotides for the inhibition of vegf expression |
| 05/30/2001 | EP1102838A2 A method of modulating the efficiency of translation termination and degradation of aberrant mrna involving a surveillance complex comprising human upf1p, eucaryotic release factor 1 and eucaryotic release factor 3 |
| 05/30/2001 | EP1102739A1 Glucocorticoid and thyroid hormone receptor ligands for the treatment of metabolic disorders |
| 05/30/2001 | EP1102597A1 Multivalent agonists, partial agonists, inverse agonists and antagonists of the 5ht 4 receptors |
| 05/30/2001 | EP1102584A2 Antioxidant, antiproliferous composition, comprising a carnitine and a carotenoid |
| 05/30/2001 | EP0929292B1 Method and composition for rewetting contact lenses and relieving eye dryness |
| 05/30/2001 | EP0817610B1 Sterile ophthalmological gel preparation applicable in drops and process for producing it |
| 05/30/2001 | EP0687176B1 Use of riluzole for treating aids-related neural disorders |
| 05/30/2001 | CN1297436A Substd. pyrrolidine hydroxamate metalloprotease inhibitors |
| 05/30/2001 | CN1297432A Substd. amides, their production and their use |
| 05/30/2001 | CN1297359A Ophthalmic composition comprising beta-blocker |
| 05/30/2001 | CN1296815A Eye drops of diclofenac sodium |
| 05/30/2001 | CN1066339C Use of theaflavine for prepn. of medicine for treating deafness |
| 05/29/2001 | US6239288 Biphenyl hydroxy imino butyric acids and their derivatives for treating arthritis |
| 05/29/2001 | US6239147 To treat cns, gastrointestinal and other disorders. substance p antagonists having improved activity and fewer side effects, treatment of emesis induced by antineoplastic agents, isochroman ring |
| 05/29/2001 | US6239132 Thrombin inhibitors |
| 05/29/2001 | US6239113 Topical treatment or prevention of ocular infections |
| 05/29/2001 | US6239102 Concentrate comprising, as active agent, (3'-desoxy-3-oxo-mebmc)1-(val)2-cyclosporin, stabilizer selected from oleic acid or palmitoyl oleoyl phosphatidyl glycerol or salts thereof, ethanol |